No abstract

In implant associated lymphomas, prothesis explantation and complete excision of any residual mass are the recommended approaches. Systemic chemotherapy is generally recommended for patients with locally advanced and disseminated diseases, mainly using treatment protocols routinely adopted for systemic ALCLs (e.g., CHOP, CHOEP, etc.). Limited data are available regarding the treatment of non-mammary implant associated ALCL. The first documented joint prosthesis associated ALCL patient was lost to follow-up while no adjuvant chemotherapy was considered in gluteal implant associated ALCL, however the patient was disease free. Our patient has received chemotherapy (CHOP regime) and was doing well at last follow-up.In conclusion, oncologists and pathologists should be more observant in patients who undergo silicone or non-silicone device implantation as these surgical procedures will continue to rise in various non-neoplastic and neoplastic lesions. Though the morphology and immunophenotyping of mammary and non-mammary implant associated ALCL is similar to ALK-negative ALCL, such cases need to be further investigated for DUSP22 or TP63 rearrangements as the latter carries dismal prognosis. The exact biological relationship between the implant device and ALCL needs to be addressed and explored at the molecular level.